X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Baupost Group
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 25, 2021
Details:
The new capital, alongside company's recently announced collaboration with Eisai supports lead small molecule programs targeting amyloid-β and α-synuclein, with first clinical candidate for amyloid-β in Q1 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Exosome-mediated RNAi
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The recently issued US patent provides broad coverage for pharmaceutical compositions comprising exosomes containing nucleic acid-based therapeutics, such as RNAi agents and antisense oligonucleotides, which have been loaded by electroporation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RNA interference
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,230.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration June 09, 2020
Details:
During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: AstronauTx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2020
Details:
The alliance will focus on identifying small molecule drugs able to modulate astrocyte biology to expand AstronauTx's pipeline of novel therapeutic candidates for the treatment of Alzheimer's disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $274.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 29, 2020
Details:
Collaboration initiates second Roche program utilizing Icagen’s ion channel drug discovery platform.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
